Pharmaceutical intermediates
Dabigatran Etexilate Intermediates
3 pharmaceutical intermediates for Dabigatran Etexilate. Indication: Embolism; Venous Thrombosis; Stroke.
About Dabigatran Etexilate
- Originator
- Breckenridge Pharmaceutical Inc
- Indication
- Embolism; Venous Thrombosis; Stroke
- Approved Date
- 12/19/2024
Available intermediates
3 intermediates currently listed for Dabigatran Etexilate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Methylamino-3-nitrobenzoic acid | 41263-74-5 | / | / |
| N-(4-Cyanophenyl)glycine | 42288-26-6 | / | / |
| 3-[(3-Amino-4-methylaminobenzoyl)pyridin -2-ylaminolpropionic acidethyl ester | 212322-56-0 | / | / |
Building toward Dabigatran Etexilate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →